Skip to main content
×
×
Home

One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis

  • Hiroyoshi Takeuchi (a1), Navot Kantor (a2), Marcos Sanches (a3), Gagan Fervaha (a4), Ofer Agid (a5) and Gary Remington (a6)...
Abstract
Background

As definitions of relapse differ substantially between studies, in investigations involving data aggregation, total scores on clinical rating scales provide a more generalisable outcome.

Aims

To compare total symptom trajectories for antipsychotic versus placebo treatment over a 1-year period of maintenance treatment in schizophrenia.

Method

Randomised controlled trials with antipsychotic and placebo treatment arms in patients with stable schizophrenia that reported Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale total scores at more than one time point were included. Meta-regression analyses were employed using a mixed model.

Results

A total of 11 studies involving 2826 patients were included. Meta-regression analyses revealed significant interactions between group and time (PS<0.0001); both standardised total scores and per cent score changes remained almost unchanged in patients continuing antipsychotic treatment, whereas symptoms continuously worsened over time in those switching to placebo treatment.

Conclusions

When considering long-term antipsychotic treatment of schizophrenia, clinicians must balance symptomatic and functional outcomes.

Copyright
Corresponding author
Hiroyoshi Takeuchi, Schizophrenia Division, Complex Care & Recovery Program, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, M5T 1R8, Canada. Email: hirotak@dk9.so-net.ne.jp
Footnotes
Hide All

See editorial, pp. 127–129, this issue.

Declaration of interest

H.T. has received manuscript fees from Sumitomo Dainippon Pharma. O.A. has received speaker's honoraria from Eli Lilly & Company USA, Eli Lilly Canada, Janssen-Ortho (Johnson & Johnson), Lundbeck, Mylan Pharmaceuticals, Novartis, Sepracor Inc. and Sunovion, and consultant fees from BMS, Eli Lilly & Company USA, Eli Lilly Canada, Janssen-Ortho (Johnson & Johnson), Lundbeck, Novartis, Otsuka, Roche, Sepracor Inc. and Sunovion, and research support from Boehringer Ingelheim, Neurocrine Biosciences, Janssen-Ortho (Johnson & Johnson), Otsuka, Pfizer Inc. and Sunovion. G.R. has received research support from Novartis, Medicure and Neurocrine Bioscience, consultant fees from Laboratorios Farmacéuticos ROVI, Synchroneuron and Novartis, and speaker's fees from Novartis.

Footnotes
References
Hide All
1 Takeuchi, H, Suzuki, T, Uchida, H, Watanabe, K, Mimura, M. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res 2012; 134: 219–25.
2 Leucht, S, Tardy, M, Komossa, K, Heres, S, Kissling, W, Salanti, G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063–71.
3 Gleeson, JFM, Alvarez-Jimenez, M, Cotton, SM, Parker, AG, Hetrick, S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res 2010; 119: 7988.
4 Kishimoto, T, Agarwal, V, Kishi, T, Leucht, S, Kane, JM, Correll, CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 2013; 18: 5366.
5 Kishimoto, T, Robenzadeh, A, Leucht, C, Leucht, S, Watanabe, K, Mimura, M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2014; 40: 192213.
6 Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76.
7 Overall, JE, Gorham, DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799812.
8 Agid, O, Kapur, S, Arenovich, T, Zipursky, RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003; 60: 1228–35.
9 Sherwood, M, Thornton, AE, Honer, WG. A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics. Int J Neuropsychopharmacol 2006; 9: 357–66.
10 Suzuki, T, Remington, G, Arenovich, T, Uchida, H, Agid, O, Graff-Guerrero, A, et al. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Br J Psychiatry 2011; 199: 275–80.
11 Sherwood, M, Thornton, AE, Honer, WG. A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine. J Psychopharmacol 2012; 26: 1175–84.
12 Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
13 Higgins, JPT, Green, S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011 (http://handbook.cochrane.org).
14 Leucht, S, Davis, JM, Engel, RR, Kane, JM, Wagenpfeil, S. Defining ‘response’ in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007; 32: 1903–10.
15 Obermeier, M, Mayr, A, Schennach-Wolff, R, Seemüller, F, Möller, H-J, Riedel, M. Should the PANSS be rescaled? Schizophr Bull 2010; 36: 455–60.
16 Leucht, S, Kissling, W, Davis, JM. The PANSS should be rescaled. Schizophr Bull 2010; 36: 461–2.
17 Furukawa, TA, Levine, SZ, Tanaka, S, Goldberg, Y, Samara, M, Davis, JM, et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 2015; 72: 1421.
18 Arato, M, O'Connor, R, Meltzer, HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002; 17: 207–15.
19 Beasley, CM, Sutton, VK, Hamilton, SH, Walker, DJ, Dossenbach, M, Taylor, CC, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003; 23: 582–94.
20 Clark, ML, Huber, WK, Hill, D, Wood, F, Costiloe, JP. Pimozide in chronic schizophrenic outpatients. Dis Nerv Syst 1975; 36: 137–41.
21 Cooper, SJ, Butler, A, Tweed, J, Welch, C, Raniwalla, J. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology (Berl) 2000; 150: 237–43.
22 Fu, D-J, Turkoz, I, Simonson, RB, Walling, DP, Schooler, NR, Lindenmayer, J-P, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry 2015; 76: 253–62.
23 Hough, D, Gopal, S, Vijapurkar, U, Lim, P, Morozova, M, Eerdekens, M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010; 116: 107–17.
24 Kane, JM, Sanchez, R, Perry, PP, Jin, N, Johnson, BR, Forbes, RA, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012; 73: 617–24.
25 Kramer, M, Simpson, G, Maciulis, V, Kushner, S, Vijapurkar, U, Lim, P, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007; 27: 614.
26 Pigott, TA, Carson, WH, Saha, AR, Torbeyns, AF, Stock, EG, Ingenito, GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048–56.
27 Rui, Q, Wang, Y, Liang, S, Liu, Y, Wu, Y, Wu, Q, et al. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 53C: 4553.
28 Tandon, R, Cucchiaro, J, Phillips, D, Hernandez, D, Mao, Y, Pikalov, A, et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J Psychopharmacol 2016; 30: 6977.
29 Gitlin, M, Nuechterlein, K, Subotnik, KL, Ventura, J, Mintz, J, Fogelson, DL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158: 1835–42.
30 Zipursky, RB, Menezes, NM, Streiner, DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 2014; 152: 408–14.
31 Mayoral-van Son, J, de la Foz, VO-G, Martinez-Garcia, O, Moreno, T, Parrilla-Escobar, M, Valdizan, EM, et al. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals. J Clin Psychiatry 2016; 77: 492500.
32 Harrow, M, Jobe, TH, Faull, RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med 2012; 42: 2145–55.
33 Moilanen, J, Haapea, M, Miettunen, J, Jääskeläinen, E, Veijola, J, Isohanni, M, et al. Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication – a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. Eur Psychiatry 2013; 28: 53–8.
34 Wils, RS, Gotfredsen, DR, Hjorth⊘j, C, Austin, SF, Albert, N, Secher, RG, et al. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res 2017; 182: 42–8.
35 Inderbitzin, LB, Lewine, RR, Scheller-Gilkey, G, Swofford, CD, Egan, GJ, Gloersen, BA, et al. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. Am J Psychiatry 1994; 151: 1753–9.
36 Takeuchi, H, Suzuki, T, Remington, G, Bies, RR, Abe, T, Graff-Guerrero, A, et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull 2013; 39: 993–8.
37 Viguera, AC, Baldessarini, RJ, Hegarty, JD, van Kammen, DP, Tohen, M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54: 4955.
38 Leucht, S, Kane, JM, Kissling, W, Hamann, J, Etschel, E, Engel, RR. What does the PANSS mean? Schizophr Res 2005; 79: 231–8.
39 Murray, RM, Quattrone, D, Natesan, S, van Os, J, Nordentoft, M, Howes, O, et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry 2016; 209: 361–5.
40 Wunderink, L, Nieboer, RM, Wiersma, D, Sytema, S, Nienhuis, FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013; 70: 913–20.
41 Wunderink, L, Nienhuis, FJ, Sytema, S, Slooff, CJ, Knegtering, R, Wiersma, D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68: 654–61.
42 Jaaskelainen, E, Juola, P, Hirvonen, N, McGrath, JJ, Saha, S, Isohanni, M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013; 39: 1296–306.
43 Harrow, M, Jobe, TH. Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull 2013; 39: 962–5.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 1
Total number of PDF views: 136 *
Loading metrics...

Abstract views

Total abstract views: 263 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 19th June 2018. This data will be updated every 24 hours.

One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis

  • Hiroyoshi Takeuchi (a1), Navot Kantor (a2), Marcos Sanches (a3), Gagan Fervaha (a4), Ofer Agid (a5) and Gary Remington (a6)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *